As shown in 34 randomly chosen human glioma cell lines, the status of TP53, p16, p14ARF, and PTEN tumor-suppressor genes could participate in biological pathways that are functioning separately/independently in glioma cells and did not correlate with tumorigenicity or any clinical parameters [41]. This evidence concerns the gene PTEN and central nervous system cancer.